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ABSTRACT
Osteoclasts are bone-resorbing cells derived from the monocyte/
macrophage lineage. Excess osteoclast activity leads to reduced
bone mineral density, a hallmark of diseases such as osteoporosis.
Processes that regulate osteoclast activity are therefore targeted in
current osteoporosis therapies. To identify and characterize drugs for
treatment of bone diseases, suitable in vivo models are needed to
complement cell-culture assays. We have previously reported
transgenic medaka lines expressing the osteoclast-inducing factor
receptor activator of nuclear factor κB ligand (Rankl) under control of
a heat shock-inducible promoter. Forced Rankl expression resulted
in ectopic osteoclast formation, as visualized by live imaging in
fluorescent reporter lines. This led to increased bone resorption and a
dramatic reduction of mineralized matrix similar to the situation in
humans with osteoporosis. In an attempt to establish the medaka as
an in vivo model for osteoporosis drug screening, we treated
Rankl-expressing larvae with etidronate and alendronate, two
bisphosphonates commonly used in human osteoporosis therapy.
Using live imaging, we observed an efficient, dose-dependent
inhibition of osteoclast activity, which resulted in the maintenance
of bone integrity despite an excess of osteoclast formation. Strikingly,
we also found that bone recovery was efficiently promoted after
inhibition of osteoclast activity and that osteoblast distribution was
altered, suggesting effects on osteoblast-osteoclast coupling. Our
data show that transgenic medaka lines are suitable in vivo models
for the characterization of antiresorptive or bone-anabolic
compounds by live imaging and for screening of novel osteoporosis
drugs.
KEY WORDS: Osteoporosis, Bone modeling, Remodeling,
Homeostasis, Osteoblast-osteoclast coupling, Medaka
INTRODUCTION
Bone is a highly dynamic tissue that undergoes continuous
remodeling to retain its stability and rigidity. The resorption of
mineralized bone matrix by osteoclasts concurs with deposition of
new bone by osteoblasts. To obtain homeostasis and prevent
disequilibrium, the number and activities of various bone cell types
need to be tightly coordinated. The concept of a ‘basic multicellular
unit’ that underlies bone remodeling implies a feedback between
different bone cells (Harada and Rodan, 2003). Accordingly,
increased bone resorption also stimulates an increase of bone
formation and vice versa. Interactions between osteoclasts and
osteoblasts occur during all phases of bone formation and
remodeling and are crucial for bone homeostasis (reviewed by
Charles and Aliprantis, 2014). In disease conditions, cell
communication between osteoblasts and osteoclasts is perturbed.
In osteoporosis, for example, this leads to increased osteoclast
activity and bone resorption, causing reduced bone mineral density
and increased fracture risk. Also, age-related bone loss is associated
with significant changes in bone remodeling characterized by
decreased bone formation relative to bone resorption, resulting in
increased bone fragility (e.g. see Khosla and Riggs, 2005;
Manolagas, 2010). In the USA, 55% of people 50 years of age
and older have an increased risk to develop osteoporosis, and of the
approximately 10 million Americans with osteoporosis, 80% are
women (Nanes and Kallen, 2009).
Current osteoporosis therapies aim to increase bone mass by
treatment with either bone-anabolic or antiresorptive drugs.
Although anabolic therapies are presently limited to intermittent
parathyroid hormone (iPTH) treatment, several antiresorptive
therapies are available. Among these, bisphosphonates (BPs) are
currently the most frequently used drugs in human osteoporosis
therapy (Rogers et al., 2011). BPs chelate Ca2+ on the bone surface,
affect bone metabolism and lead to a general reduction in bone
turnover (Jobke et al., 2014). When osteoclasts are in their
resorptive phase, a highly acidic microenvironment is created.
This facilitates the release of BPs in the resorption lacunae and leads
to high local concentrations of BPs that are then internalized into
osteoclasts by endocytosis.
Etidronate is a first-generation non-nitrogenous BP that forms
cytotoxic ATP analogs after internalization. These block energy
metabolism and impair osteoclast function, eventually triggering
caspase-mediated apoptosis (Benford et al., 2001; Dominguez
et al., 2011; Ebetino et al., 2011). The nitrogen-containing
alendronate is a member of the second BP generation that inhibits
the mevalonate pathway and sterol biosynthesis and prevents
prenylation of small GTPases (Luckman et al., 1998). This disrupts
the osteoclast cytoskeleton and prevents formation of a ruffled
border, resulting in the loss of resorptive osteoclast function
(Ebetino et al., 2011; Jobke et al., 2014; Rogers et al., 2011).
Besides blocking osteoclast function and survival, BPs also have a
deleterious effect on bone formation in human patients. Long-term
use of BPs results in brittle bone and increased risk of bone
fractures (Rogers et al., 2011). Therefore, more efficient drugs
would aid efforts to alleviate bone deficiencies more specifically,
and in vivo models are needed to identify and characterize these
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Compared with cell-culture settings, in vivo models provide
valuable insight into the multicellular networks implicated in bone
homeostasis. Zebrafish and medaka have become popular models in
bone research (reviewed by Apschner et al., 2011; Mackay et al.,
2013). Their almost transparent embryos and larvae allow live
imaging at high temporal and spatial resolution during bone
modeling and remodeling (Apschner et al., 2014; To et al., 2012).
Teleost osteoblasts and osteoclasts share many features with their
mammalian counterparts. Like mammals, teleost fish form bone
through chondral and intramembranous bone formation and
undergo bone remodeling (Witten and Huysseune, 2009). We
previously reported generation of transgenic medaka that express
fluorescent reporters in bone cells under control of various
osteoblast- and osteoclast-specific promoters; this includes
osteoblast progenitors (collagen type 10a1, col10a1; Renn et al.,
2013), premature and mature osteoblasts (osterix, osx and
osteocalcin, osc; Renn and Winkler, 2009) and osteoclasts
(cathepsin K, ctsk; To et al., 2012). We also generated a
transgenic line that expresses the osteoclast-inducing factor
receptor activator of nuclear factor κB ligand (Rankl) under
control of a heat-inducible promoter (To et al., 2012). Induction of
Rankl in this system results in ectopic formation of activated
osteoclasts. This leads to increased bone resorption and a severe
osteoporosis-like phenotype, with drastically reduced
mineralization in the vertebral bodies. This unique transgenic
model allows in vivo visualization of osteoclast formation and
osteoblast-osteoclast interaction by live imaging (To et al., 2012).
Bone-anabolic compounds have been tested in fish models in the
past (Barrett et al., 2006; Fleming et al., 2005). These early studies
established the suitability of fish larvae to assess the effects of
compounds on the mineralized skeleton efficiently. In the present
study, we used live imaging in medaka to visualize osteoblast and
osteoclast behavior in the presence of BPs in vivo. We report that
BPs efficiently block osteoclast activity and promote bone recovery
in this unique transgenic model.
RESULTS
Etidronate and alendronate inhibit osteoclast activity in
medaka and prevent mineralization loss after Rankl
induction
Etidronate and alendronate have previously been shown to maintain
skeleton mineralization in a zebrafish model for glucocorticoid-
induced osteoporosis, but their effect on bone cells remained
unknown (Barrett et al., 2006; Fleming et al., 2005). We used
similar BP concentrations to determine the effect of BPs on
osteoclast formation and activity in bone transgenic medaka
reporter lines. Dose-response studies showed that a concentration
of 10 μg/ml for etidronate and 50 μg/ml for alendronate was most
efficient to affect osteoclast activity in medaka (see Fig. S1).
To test how BP treatment affects osteoclast activity in vivo, we
analyzed rankl:HSE:CFP/ctsk:nlGFP double transgenic medaka
larvae. Larvaewere heat shocked at 9 days postfertilization (dpf ) for
1.5 h to induce ectopic osteoclast formation, as described previously
(To et al., 2012). The heat shock slightly delayed larval
development, as evident by the extent of mineralization in the
caudal fin rays. Importantly, however, this delay was identical in
non-BP-treated and BP-treated larvae (Fig. S2). Wild-type control
larvae or transgenic larvae without Rankl induction develop a
mineralized vertebral column at 11 dpf, with mineralized dorsal
neural arches and vertebral centra (Fig. 1A-C″). No ctsk:nlGFP-
expressing osteoclasts are visible in the trunk region in control
larvae at this stage (Fig. 1A,C). After heat shock-induced Rankl
expression, excessive numbers of ectopic ctsk:nlGFP-expressing
osteoclasts were found covering vertebral bodies and neural arches
(Fig. 1D-F″). Accumulation of these tartrate-resistant acid
phosphatase (TRAP)- and CathepsinK (Ctsk)-positive osteoclasts
(see To et al., 2012) results in enhanced resorption of mineralized
matrix, which consequently leads to the absence of alizarin
complexone (ALC)-stained neural arches and large non-
mineralized cavities in the notochordal sheath and vertebral centra
in 82.2% of the analyzed larvae (n=52; arrowheads in Fig. 1F).
Fig. 1. Osteoclast formation and vertebral body
mineralization after Rankl induction. (A,B) Absence of
ctsk:nlGFP-expressing osteoclasts in vertebral bodies in
ctsk:nlGFP larvae at 11 dpf (A) and intact mineralization (B)
without Rankl induction. (C-C″) Confocal stack of area boxed
in (A,B), showing ALC-stained intact vertebral bodies (C),
GFP autofluorescence of pigment cells (C′) and an overlay
with GFP (C″). (D,E) Ectopic osteoclast formation at 11 dpf,
after Rankl induction at 9 dpf in rankl:HSE:CFP/ctsk:nlGFP
larvae (D) and ALC-stained mineralization (E).
(F-F″) Confocal stack of area boxed in (D,E), showing
absence of mineralized neural arches and cavities in
vertebral centra (arrowheads in F), where active osteoclasts
cover the vertebral bodies (overlay in F″). Scale bars: 50 μm.
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Next, transgenic larvae were treated with etidronate and
alendronate (Fig. 2). Treatment started on the same day as the heat
shock (9 dpf ) and continued for 2 days. BP treatment did not affect
overall osteoclast formation (Fig. 2A,D). However, in 56.3% of
BP-treated larvae the osteoclast distribution appeared reduced,
especially in axial skeleton regions (see Fig. S3). This raises the
possibility that BPs cause a delay in either formation or maturation
of induced osteoclasts. Larvae with an equal extent of ectopic
osteoclast formation were then analyzed after BP treatment
for mineralization of the neural arches and vertebral centra
(Fig. 2B,C,E,F) and compared with Rankl-induced larvae without
BP treatment (Fig. 1E,F). The number of larvae with mineralization
Fig. 2. Treatment with etidronate or alendronate blocks osteoclast function and bone resorption. (A-C″) Expression of ctsk:nlGFP in ectopic osteoclasts
after addition of etidronate on the same day as Rankl induction. (C-C″) Confocal imaging shows vertebral bodies with almost intact neural arches (arrowheads in
C), in the presence of abundant ctsk:nlGFP-positive osteoclasts (C′). (D-F″) Expression of ctsk:nlGFP in osteoclasts after addition of alendronate on the same day
as Rankl induction. (F-F″) Confocal imaging shows intact vertebral bodies with neural arches (arrowheads in F), in the presence of ectopic osteoclasts (F′).
(G) Confocal image of ctsk:nlGFP-expressing osteoclasts after Rankl induction without BP treatment (taken from the same larvae as in Fig. 1F′, boxed area).
(H, I) Confocal image of Rankl-induced osteoclasts after etidronate or alendronate treatment, respectively (taken from the same larvae shown in C′ and F′, boxed
areas). (J) Statistical analysis of larvae with intact neural arches at 11 dpf, without Rankl induction (blue), after Rankl induction (red), after Rankl induction with
etidronate (green; *0.01<P<0.05) or alendronate (purple; **P<0.01) treatment. (K-M) Transverse plastic sections (2 µm) through the notochord (no), spinal cord
(sc) and the basis of the anteriormost neural arches at the same cross-sectional level, in−Rankl control larvae (K) and in larvae after Rankl induction without (L) or
with (M) BP treatment. The base of the neural arches is labeled with a black arrowhead, osteoblasts are marked by black arrows and osteoclasts by white
arrowheads. The basis of the bony arches is outlined by a dotted line. The sections in K,M are slightly oblique so that the neural arches of only one side can be
seen. Scale bars: 50 μm in C,F; 30 µm in K-M.
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defects significantly decreased after treatment with etidronate
(60.0%, n=57; Fig. 2C,J) and alendronate (51.5%, n=49; Fig. 2F,J).
These rescued larvae showed almost completely intact neural arches
and centra in the presence of ectopic osteoclasts (Fig. 2C-C″,F-F″).
Notably, the remaining larvae showed mineralization defects that
were qualitatively less severe than those observed in non-BP-treated
+Rankl larvae (Fig. S4). Also, the general morphology of
osteoclasts appeared to change after BP treatment. When
compared with cells without BP treatment (Fig. 2G), cells after
BP treatment often appeared less extended and more compacted
(Fig. 2H,I). In histological sections of −Rankl control larvae, the
basis of neural arches was surrounded by active osteoblasts, with no
indication of resorption (Fig. 2K). In the +Rankl non-BP-treated
group, larvae with severe vertebral defects showed areas where
neural arches were resorbed and fenestrated by what appeared to be
multinucleated osteoclasts (Fig. 2L, white arrowheads), leading to
the absence of neural arches in ALC-stained specimens (Fig. 1F). In
BP-treated animals, by contrast, intact arches were seen
histologically (Fig. 2M), confirming the observations shown with
ALC staining in Fig. 2C,F. Etidronate also prevented mineralization
defects in arches when Rankl was induced at a much later time point
(15 dpf; Fig. S5). These findings strongly suggest that treatment
with etidronate and alendronate efficiently interferes with osteoclast
function after induction by transgenic Rankl expression.
Bisphosphonates induce morphological changes in medaka
osteoclasts
When Rankl expression is triggered by heat shock at 9 dpf, the
induced ctsk:nlGFP-expressing osteoclasts usually persist for
several days (Fig. 3A), but most of the cells have disappeared at
15 dpf (To et al., 2012; Fig. 3A′). By contrast, we observed that a
considerable fraction of etidronate-treated and alendronate-treated
embryos continued to show ctsk:nlGFP-positive osteoclasts (n=7/
95, 7.4% for etidronate and n=15/118, 12.7% for alendronate;
Fig. 3C,D). These cells aggregated into large clusters and appeared
to fuse into giant multinucleated cells (Fig. 3B′-E″; DAPI stain in
Fig. 3E′,E″). Light and transmission electron microscopic
observations confirmed the occurrence of cell aggregates and the
possible presence of multinucleated cells within these aggregates
(Fig. 3F,G). Similar cell behavior, i.e. aggregation and possible
fusion, was not observed in rankl:HSE:CFP/ctsk:EGFP double
transgenic medaka larvae without BP treatment (Fig. 3A′). This
suggests that BPs can extend the lifetime of osteoclasts in medaka
and possibly promote cell fusion. Interestingly, ‘giant-osteoclasts’
with extensively increased cell size and excess nuclei have been
described in human osteoporosis patients after long-term BP
treatment (Jobke et al., 2014). Thus, BPs can trigger effects in
medaka that are similar to those observed in human patients.
Bisphosphonate treatment stimulates bone recovery in
medaka
We next wanted to test whether BP treatment also affects bone
remineralization. For this, we started BP treatment 3 days after
osteoclasts had been induced by transgenic Rankl expression. In
a similar manner to the previous experiment, rankl:HSE:CFP
transgenic larvae were subjected to heat shock at 9 dpf, except that
the heat shock was extended to 2 h. In these conditions, ectopic
osteoclasts are efficiently induced and more than 90% of the larvae
Fig. 3. BPs induce morphological changes in osteoclasts. (A,A′) ctsk:nlGFP expression in one rankl:HSE:CFP/ctsk:nlGFP larva at 11 and 15 dpf, 2 and
6 days after Rankl induction, respectively. Note the reduction in the number of nlGFP-positive cells at 15 dpf. (B,B′) ctsk:nlGFP expression in one larva at 11 and
15 dpf, after Rankl induction and etidronate treatment. Note aggregation of nlGFP-positive cells (arrowhead). (C) ctsk:nlGFP expression in larvae at 15 dpf, after
etidronate treatment. (C′) Confocal stack of area boxed in C showing accumulation of small osteoclasts (left and middle; arrows) and giant ctsk:nlGFP-expressing
cell (right). (D) Larvawith extensive aggregates of ctsk:nlGFP-expressing cells after alendronate treatment. (E-E″) ctsk:nlGFP-expressing cell aggregates stained
with DAPI. (F) Ventral lesion (white arrowheads) in the notochord (no) after Rankl induction and BP treatment at 15 dpf (2 µm parasagittal plastic section). The
notochordal sheath (ns) is disrupted, and notochordal cells are bulging out. They are delimited by a thin layer of matrix (black arrowheads). Outside, multiple nuclei
are visible. (G) A higher magnification of this region in transmission electron microscopy shows that at least some nuclei (white asterisks) appear to belong to a
single cell as they appear not to be separated by cell membranes. They adjoin the bone layer (bo) deposited outside the notochordal sheath (ns). Scale bars:
50 μm in C′; 20 μm in E; 15 µm in F; 2 µm in G.
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exhibit a complete loss of mineralized neural arches at 12 dpf when
compared with non-heat-shocked controls (data not shown). We
then started BP treatment in larvae with strong mineralization
defects at 12 dpf, as analyzed by ALC staining. Larvae were
subjected to a second heat shock at 14 dpf to induce severe lesions
in the centra. The second heat shock was performed to enhance the
effect of Rankl induction, and thereby, make the effect of BP
treatment more obvious. BP treatment was done from 12 to 16 dpf
(i.e. 3 days after osteoclast induction) in order to detect any effects
on bone recovery (Fig. 4). De novo mineralization was analyzed by
successively staining larvae with calcein at 16 dpf. This allows
previously existing mineralized (stained with ALC, red) matrix to be
distinguished from de novo mineralized matrix (stained with
calcein, green). Accordingly, in non-heat-shocked control
embryos without BP treatment, newly mineralized matrix could
be detected at the tips of the extending neural arches and around the
Fig. 4. Etidronate and alendronate
accelerate bone recovery after
blocking bone resorption in rankl:
HSE:CFP larvae. (A,B) Normal
development of centra and arches
from 12 dpf (ALC stained) to 16 dpf
(calcein stained). (C-C″) Confocal
stack of area boxed in (A,B), showing
de novo mineralization at the tip of
neural arches (arrowheads; calcein
stained; C″) and around the
notochordal sheath. (D-F) ALC-
stained bone matrix at 12 dpf, 3 days
after Rankl induction. Note lesions in
the neural arches and centra (arrows).
A second heat shock was carried out at
14 dpf. (D′-F′) At 16 dpf, the same
larvae were stained with calcein to
visualize newly formed mineralized
bone matrix without (D-D″) and with
etidronate (E-E″) or alendronate (F-F″)
treatment. At this stage, lesions in
centra are repaired (D-F), but neural
arches are remineralized only after BP
treatment (arrowheads; E″,F″) and
not without BP treatment (D″).
(G) Statistical analysis showing the
percentage of larvae with neural
arches at 16 dpf, after Rankl induction
(blue), and after Rankl induction and
etidronate (red) or alendronate (green)
treatment. **P<0.01. Scale bars:
50 μm.
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notochordal sheath (Fig. 4A-C″). For +Rankl non-BP-treated
control larvae, repair of lesions in the centra region can be
observed, but only 14.3% of heat-shocked embryos developed
neural arches (Fig. 4D-D″). By contrast, with BP treatment, 68.4%
larvae after etidronate (Fig. 4E-E″,G) and 62.5% after alendronate
(Fig. 4F-F″,G) treatment showed partly recovered neural arches at
16 dpf. Compared with arches in −Rankl non-BP-treated control
larvae (Fig. 4C″), the arches in BP-treated larvae were composed
exclusively from de novo mineralized matrix as evident by uniform
calcein staining in absence of any ALC label (Fig. 4E″,F″). These
findings suggest that in medaka, BPs stimulate bone recovery by
blocking osteoclast function.
In severe cases, +Rankl non-BP-treated control larvae showed
newly mineralized matrix only at the edges of the lesions induced
in centra (Fig. S6A-A″). By contrast, larvae after etidronate and
alendronate treatment showed an almost complete de novo
remineralization of cavities in the centra (Fig. S6B″-C″). This
suggests that after blocking osteoclast activity in medaka by BPs,
coexisting osteoblasts efficiently remineralize damaged bone
matrix, resulting in bone recovery.
Bisphosphonate treatment affects osteoblast distribution
Osteoblast-osteoclast coupling implies a tightly coordinated
interaction between both cell types in order to maintain
appropriate cell numbers and bone homeostasis. In human
osteoporosis patients, long-term BP treatment reduces bone
formation by osteoblasts, but the underlying cellular mechanisms
remain unclear (reviewed by Charles and Aliprantis, 2014). We
therefore tested whether osteoblast-osteoclast coupling is affected
by BP treatment in medaka. Specifically, we assessed whether the
behavior of osteoblasts expressing osterix (osx) is altered when
larvae are treated with BPs. For this, we subjected rankl:HSE:CFP/
ctsk:nlGFP/osx:mCherry triple transgenic medaka larvae to two
successive rounds of heat shock at 9 and 14 dpf and assessed
formation and distribution of osx-expressing osteoblasts with and
without BP treatment. As controls, neither heat shock alone
(without Rankl) nor BP treatment alone affected distribution of
osx:mCherry-positive osteoblasts (Fig. S7). Significant differences
in the distribution of osx-positive osteoblasts were observed
between larvae without (Fig. 5A-C) and with ectopic osteoclast
formation (Fig. 5D-D″) at 12 dpf (see also Renn et al., 2013). The
number of osx-positive cells was strongly reduced along the neural
arches, and instead, osx-positive cells accumulated in the centra
(Fig. 5D′) along with the presence of active osteoclasts (Fig. 5D″).
At 16 dpf, osteoblasts were completely absent from the neural
arches in Rankl-induced larvae without BP treatment and were only
found in the centra (Fig. 5E′-E″). By contrast, in larvae treated with
BPs from 12 to 16 dpf, osteoblasts were present along the neural
arches and were less prominent in the centra (Fig. 5F′,G′).
Intriguingly, osteoclasts were abundant in these embryos with
Rankl expression (Fig. 5F,G). Together, these results suggest that
Rankl-induced, active osteoclasts drive osteoblasts to lesion sites
inside the centra. In the presence of BPs, however, many osteoblasts
remain at the arches and contribute to their mineralization.
DISCUSSION
Zebrafish and medaka have become popular models in bone
research. They complement each other and offer a unique
combination of large-scale genetics with live imaging to identify
and characterize novel factors involved in bone formation and
remodeling (Mackay et al., 2013). Although the zebrafish has
cellular bones containing osteocytes and offers a large number of
well-characterized bone mutants (Apschner et al., 2014; Mackay
et al., 2013), the medaka is characterized by acellular bone without
osteocytes and provides many useful transgenic bone reporter lines
(Takeyama et al., 2014; To et al., 2012). The almost transparent fish
embryos and larvae allow visualization of cellular processes by live
imaging that are not accessible in mammalian model systems. Large
numbers of fish embryos and larvae can easily be obtained on a
daily basis and maintained in minimal volumes of simple media.
This makes them ideal models for high-content and low-cost
screening of clinically relevant compounds (for review see Ablain
and Zon, 2013). Despite these obvious advantages, fish models
have rarely been used so far to characterize the effect of bone-
anabolic or antiresorptive drugs on osteoblasts and osteoclasts
in vivo.
We previously reported two transgenic medaka osteoporosis
models. In the first model, the number of osteoblasts was reduced by
conditional cell ablation, leading to reduced bone formation
(Willems et al., 2012). In the second model, osteoclast formation
was induced by ectopic Rankl expression, leading to increased bone
resorption and reduced mineralization of bones and the notochordal
sheath (To et al., 2012). In the present study, we used this latter
model to test the effects of BPs on osteoclast formation and activity.
Our data show that treatment with etidronate or alendronate prevents
bone loss in transgenic medaka that is caused by ectopic osteoclasts
and stimulates bone recovery by blocking the bone-resorptive
function of osteoclasts. We found that Rankl induction resulted in an
upregulation of tumor necrosis factor-α expression, thus suggesting
the trigger of an inflammatory response (Fig. S8). Interestingly, this
response was attenuated in the presence of BPs, raising the
possibility that BPs modulate inflammatory reactions during
increased bone resorption.
In preclinical models and human patients, alendronate was
described to be significantly more potent than etidronate (Iwamoto
et al., 2005; Masarachia et al., 1996). In the present medaka study,
however, both BPs appeared to have similar efficacy in blocking
osteoclast activity and stimulating bone recovery; in fact, with a
higher effective dose of alendronate compared with etidronate. The
reason for this difference remains unknown but possibly reflects
biochemical differences of the affected pathways in larval compared
with adult osteoclasts. Alternatively, the possibilities cannot be
excluded that BPs bind different targets in teleosts compared with
humans or that common targets are poorly conserved.
Bone resorption requires a sealed extracellular microenvironment
and tight contact between osteoclasts and the mineralized matrix
in order to generate resorption lacunae and allow proper osteoclast
function. Using live confocal imaging, we observed osteoclasts
in the vicinity of mineralized neural arches and vertebral bodies
after BP treatment. However, these osteoclasts failed to resorb
mineralized matrix. We speculate that these osteoclasts were
probably not capable of generating sealed lacunae required for
resorption. Future histological analyseswill show themorphological
defects induced in BP-treated medaka osteoclasts.
After long-term treatment with etidronate or alendronate, changes
in osteoclast morphology were described in osteoporosis patients of
different ages and sexes. Multinucleated osteoclasts became non-
functional and underwent cell fusion, leading to ‘giant’ osteoclasts
with a two- to threefold increase in the number of nuclei (Jobke
et al., 2014; Weinstein et al., 2009). Similar observations were made
in the medaka model, where osteoclasts after BP treatment showed
reduced resorptive activity but extended lifespan and appeared to
aggregate and even fuse into multinucleated cells. Together, our
observations that BPs block osteoclast activity in medaka and
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stimulate the formation of multinucleated osteoclasts with increased
size faithfully recapitulate aspects found in human osteoporosis
patients. This therefore makes the transgenic medaka described here
an efficient and valuable in vivo model for future drug screening to
identify novel antiresorptive and bone-anabolic compounds.
We found that BP treatment did not affect general induction of
osteoclasts after transgenic Rankl induction. However, we observed
a generally less extensive distribution of osteoclasts in 56.3% of the
BP-treated larvaewhen heat shock and BPs were applied at the same
stage at 9 dpf.When BP treatment was started 1-4 days before Rankl
induction, the effect on osteoclast formation was even more
pronounced (Fig. S9). It remains to be shown whether this is the
result of a reduction in osteoclast numbers or a possible delay in
morphological maturation. Our observation raises the possibility
that osteoclast maturation depends on a proper interaction of
osteoclast precursors with mineralized matrix, which could be
impaired by matrix-bound BPs. In human BP research, focus has
been placed mainly on the effect of BPs on the inhibition of
osteoclast resorption and survival. Much less attention has been paid
to understanding the effects of BP on early osteoclast differentiation
Fig. 5. Effect of BP treatment on
osteoblast distribution.
(A-C) Expression of osx:mCherry in
osteoblasts without Rankl induction.
(C-C″) Confocal stack of area boxed in
(A,B), showing absence of ctsk:nlGFP-
expressing osteoclasts in vertebral
bodies at 12 dpf (C). osx:mCherry-
positive osteoblasts are positioned along
neural arches and the edges of centra
(arrowhead; C′). (D-D″) Position of
osx:mCherry-positive osteoblasts after
ectopic osteoclast induction. Confocal
stack showing ctsk:nlGFP cells in
vertebral bodies of Rankl-induced larvae
(arrowhead; D). Note reduction of
osx:mCherry-positive osteoblasts
around arches and increased presence
in centra (arrowheads; D′). A second
heat shock was performed at 14 dpf.
(E-G″) Osteoblast-osteoclast behavior
was observed at 16 dpf, with Rankl
induction and no BP treatment (E-E″)
and with both Rankl induction and
etidronate (F-F″) or alendronate (G-G″)
treatment. The number of osteoclasts is
reduced at 16 dpf (E,F,G) when
compared with 12 dpf (D). Note the
reduced numbers of osx:mCherry-
positive cells around neural arches but
increased numbers in the centra
(arrowheads; E′) without BP treatment.
By contrast, more osx:mCherry-positive
cells are positioned along neural
arches (arrowheads; F′,G′) after
etidronate (F-F″) or alendronate (G-G″)
treatment from 12 to 16 dpf. This
coincides with reduced numbers of osx:
mCherry-positive cells in centra. Scale
bars: 50 μm.
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and maturation. Our in vivo observations suggest that these early
differentiation stages deserve further investigation, especially in the
context of therapeutic use.
The availability of transgenic medaka lines expressing multiple
fluorescent reporters allows simultaneous visualization of different
cell types in experimental conditions such as increased bone
resorption or BP treatment. This is especially useful to characterize
osteoblast-osteoclast coupling in an in vivo context. Interestingly,
we found that the distribution of osx-positive osteoblasts was altered
after BP treatment and that these osteoblasts contributed to an
efficient bone repair. This suggests that osteoclast signaling to
maintain osteoblast numbers and distribution is affected by the
presence of BPs, at least on a short-term basis (see model in
Fig. S10). Future studies need to show whether this also persists
after long-term BP treatment and whether the osteogenic activity of
osteoblasts is affected. We have previously shown that Rankl-
induced osteoclastogenesis and subsequent resorption of the
mineralized matrix triggers a remineralization process that
involves recruitment of osteoblast progenitors to the lesion sites
(Renn et al., 2013). It will be interesting to test in detail in future
experiments whether this osteoblast progenitor recruitment is
affected by BP treatment, which would have major implications
for antiresorptive therapies in human osteoporosis patients. Our
most striking observation was that BP treatment in medaka
stimulated de novo mineralization of neural arches and vertebral
bodies. This suggests the presence of active osteoblasts in the
vertebral column that are able to repair bone lesions as soon as
osteoclast activity is blocked by BPs. Whether this reflects the
enormous regenerative potential of teleost fish or can also be found
in defective mammalian bone remains to be elucidated in future
experiments.
In mammals, BPs suppress bone formation and act as potent
mineralization inhibitors (reviewed by Charles and Aliprantis,
2014). Surprisingly, in our studies, we observed accelerated bone
recovery and rapid remineralization of bone matrix after BP
treatment in medaka, which would suggest anabolic effects of
BPs in this model. At present, we cannot explain why BPs in
medaka allow efficient remineralization of bone lesions. Future
studies using live imaging in transparent medaka larvae in different
mineralization conditions need to uncover the mechanisms
underlying the anabolic effects of BPs in this system.
Osteoporosis is a disorder primarily affecting people older than
50 years of age, and in particular, postmenopausal women (Charles
and Aliprantis, 2014). It would therefore be interesting to test the
effect of BPs on older medaka fish of both sexes, in which
osteoclasts have been activated during adult stages. Different from
the zebrafish, the medaka has heteromorphic sex chromosomes,
thus allowing a sex-specific analysis during larval and adult stages
(Nanda et al., 2002). Furthermore, bone defects have been reported
in adult medaka in a sex-specific manner (Shanthanagouda et al.,
2014). Therefore, the medaka model is excellently suited to study
the biology behind age- and sex-specific bone remodeling and to
test the efficiency of potential therapeutics. In conclusion, the
transgenic medaka model described in the present study provides
unique and novel insight into the cell interactions taking place
during bone remodeling, BP treatment and bone repair.
MATERIALS AND METHODS
Maintenance of transgenic fish
Wild-type, rankl:HSE:CFP, ctsk:nlGFP and osx:mCherry single or
compound transgenic medaka fish were kept at 26°C under a
controlled light cycle (14 h light, 10 h dark) to induce spawning.
Embryos were kept in 0.3× Danieau’s solution [19.3 mM NaCl,
0.23 mM KCl, 0.13 mM MgSO4, 0.2 mM Ca(NO3)2 and 1.7 mM
HEPES, pH 7.0] at 30°C, and medium was changed daily to ensure
normal development of the embryos. Embryos were staged
according to Iwamatsu (2004). Embryos were screened for
fluorescence reporter expression from 5 dpf onwards. All
experiments were performed in accordance with approved IACUC
protocols of the National University of Singapore (R14-293).
Bisphosphonate treatment of fish larvae
As described previously (To et al., 2012), rankl:HSE:CFP
transgenic medaka larvae at 9 dpf were subjected to heat shock at
39°C for 1.5 or 2 h to induce Rankl expression efficiently. After a
recovery period of 1 h at 30°C, larvae were screened for CFP
expression indicating successful Rankl induction. Larvae showing
expression of both CFP and ctsk:nlGFP were transferred to six-well
plates (six larvae per well) for subsequent BP treatment. Etidronate
(Sigma P5248; 5, 7.5, 10, 12.5 and 15 µg/ml) and alendronate
(Sigma A4978; 25, 37.5, 50, 62.5 and 75 µg/ml) were dissolved in
fish medium and added to the larvae at different time points after
induction of heat shock, as specified in the Results section.
Control larvae were kept in fish medium after heat shock (+Rankl
non-BP-treated control) or received no heat shock (−Rankl non-BP-
treated control; −Rankl BP-treated control). All media were
changed daily.
Live staining of mineralized matrix
For bone matrix staining, medaka larvae were incubated in 0.1%
alizarin-3-methyliminodiacetic acid (alizarin complexone, ALC;
Sigma A3882) or 0.01% calcein (Sigma C0875) in fish medium at
30°C for 1.5 or 2.5 h (for larvae at 9-17 dpf ). After incubation,
larvae were rinsed in fish medium for 30 min to 1 h before being
mounted for imaging. To ensure that all larvae were at the same
developmental stage for BP treatment, ALC staining was conducted
to count mineralized caudal fin rays. Staining was analyzed using
tetramethylrhodamine (TRITC) and GFP filter settings. Larvae with
four mineralized caudal fin rays (equivalent to 9 dpf) were selected
for further analysis.
Imaging
For live fluorescence imaging, larvae were anesthetized with 0.01%
ethyl 3-aminobenzoate methanesulfonate (tricaine; Sigma A5040)
and pictures were taken using a Nikon SMZ1000 stereomicroscope
equipped with NIS-Elements BR 3.0 software (Nikon, Japan). For
live confocal imaging, larvae were anesthetized with 0.005%
tricaine and embedded in 1.5% low-melting-point agarose in a
glass-bottomed Petri dish. Confocal pictures were taken with a Zeiss
LSM 510 Meta using 405, 488 and 543 nm laser lines for DAPI,
GFP and mCherry analysis, respectively. Imaging data were
processed using Zeiss LSM Image Browser Version 4.2.0.121,
Imaris 7.1.1 (bitplane), Image-Pro Plus 6.0, ImageJ (1.4.3.67) and
Adobe Photoshop CS6 (13.0.0.0) software.
Reverse transcription (RT)-PCR analysis
Twenty larvae at 11 dpf were used for RNA extraction using the
RNeasy Mini Kit (Qiagen 74104). Larvae without Rankl induction
andBP treatment served as controls.All RNA sampleswere subjected
to DNase I digestion. RNA was reverse transcribed using the
RevertAid First Strand cDNA Synthesis Kit (Life Technologies
K1621). β-actin was used for normalization. The fold up- or
downregulation of relative gene expression levels was calculated
from three biological replicates using ImageJ. The following primers
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were used (forward, reverse): β-actin (5′-TTCAACAGCCCTGCC-
ATGTA-3′, 5′-GCAGCTCATAGCTCTTCTCCAGGGAG-3′); and
TNF-α (5′-GGAAGATACTTGTGGTCCTGGTCT-3′, 5′-CCTCC-
CACTGATTTTGAGAAGC-3′).
Statistical analysis
The number of larvae with the indicated phenotype was recorded.
Results are presented as percentages with mean±s.d. as determined
using Excel. Two-tailed Student’s t-test was used for comparison of
groups individually and determination of significance. The level of
significance was set as follows: *0.01<P<0.05 and **P<0.01.
Histological analysis
For plastic sections and transmission electron microscopy, larvae
were either fixed in 10% formalin (Fig. 2L,M; Fig. 3F,G) or in a
mixture of 1.5% paraformaldehyde and 1.5% glutaraldehyde in
0.1 M sodium cacodylate buffer (pH.7.4; Fig. 2K) for a minimum of
2 h at room temperature. Larvae were post-fixed with osmium
tetroxide [1.25 ml OsO4, 2.5 ml sodium cacodylate buffer 0.2 M
(pH 7.4), 0.4 g saccharose, 0.04 ml CaCl2 (0.5%) and distilled H2O
to make up to 5 ml] and embedded in Epon epoxide medium.
Semithin sections (2 µm) were stained with toluidine blue. Ultrathin
sections were cut on a Reichert-OM U3 ultramicrotome, mounted
on coated, single-hole copper grids and contrasted with uranyl
acetate and lead citrate.
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